Pharmaceuticals

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.

Montara Therapeutics' new MJFF grant isn't just about Parkinson's. It's a bet on a 'BrainOnly' platform that could unlock a new era for CNS therapies.

Industrial AI leader Seeq is moving beyond mere analytics. At Conneqt 2026, it unveiled a vision to codify expertise into a new corporate asset class.

Quoin Pharmaceuticals files the first-ever drug application for Peeling Skin Syndrome, offering a glimmer of hope for patients with no treatment options.

Beyond the headlines of EHA 2026, Eli Lilly's latest data and acquisitions reveal a bold strategy to conquer the hematology market. It's a three-pronged assault.

As one major allergy drug exits, a biotech startup is testing a new path: a microneedle skin stamp. Is this the future of allergy treatment?

A new study on couples' supplements shows impressive well-being gains, but a closer look at the methodology reveals a gap between marketing and hard science.

Upcoming study results for Bayer's KERENDIA could unlock a new treatment for millions with non-diabetic chronic kidney disease, a vast and underserved group.

Frazier Healthcare Partners adds Milton Boyer as an EIR, signaling a strategic push into the complex pharmaceutical manufacturing sector with a proven operator.

Inipharm's INI-822 study leverages genetic insights for an oral MASH therapy, challenging injectable rivals and offering new hope for high-risk patients.

With real estate worth more than its stock and ambitious R&D plans, Cosmos Health claims it's undervalued. But is an unusual crypto strategy clouding the picture?

A surprising innovation is changing surgical recovery. New research shows preoperative Botox can halve opioid use for jaw surgery patients. A breakthrough?

The FDA just granted Orphan Drug status to a promising ALS therapy. It's a beacon of hope for patients and a masterclass in biotech strategy.

With positive FDA feedback and an innovative digital trial design, Herantis Pharma's HER-096 moves closer to becoming a potential disease-modifying therapy.

A breakthrough in cardiac fibrosis treatment reveals more than a new drug; it signals a systemic shift. How AI and human 'organoids' are making animal models obsolete.

With FDA backing for its novel drug HER-096, a Finnish biotech is advancing a therapy that could finally move beyond symptoms to modify Parkinson's progression.

With a seasoned drug developer at the helm, preclinical biotech FundaMental Pharma signals a major push to bring its novel TRD therapy through the clinical gauntlet.

AbbVie secures EU approval for AQUIPTA as an acute migraine therapy, creating a dual-use drug that challenges rivals and reshapes patient care strategy.

As CEO Richard Francis prepares for a key address, Teva's 'Pivot to Growth' is under the microscope. Can innovation truly outpace its generics legacy?

Canada's largest drugmaker, Apotex, launches its billion-dollar public offering, a pivotal moment for the firm and a major test for a dormant IPO market.